10-Q: Cardiff Lexington Corporation Reports Q3 2024 Results with Revenue Decline and Strategic Shift
Quarterly Report
Cardiff Lexington Corporation's Q3 2024 results show a significant revenue decrease due to weather impacts, a change in settlement realization rates, and a strategic shift towards faster cash settlements.
Summary
- Cardiff Lexington Corporation reported a net loss of $1.98 million for the third quarter of 2024, a significant decrease compared to the net income of $1.98 million in the same period of 2023.
- The company's revenue for Q3 2024 was $1.36 million, a 60.2% decrease from $3.41 million in Q3 2023, primarily due to weather-related facility closures and a strategic shift to accelerate cash settlements.
- A change in the estimated settlement realization rate from 49% to 44% resulted in a $1.65 million reduction in accounts receivable and revenue during the third quarter of 2024.
- The company's cost of sales increased by 81.5% to $1.00 million in Q3 2024, compared to $0.55 million in Q3 2023, mainly due to increased laboratory fees.
- Operating expenses increased to $0.94 million in Q3 2024 from $0.58 million in Q3 2023, driven by higher salaries, professional fees, and rent expenses.
- The company's net loss for the nine months ended September 30, 2024, was $2.39 million, compared to a net income of $2.78 million for the same period in 2023.
- Revenue for the first nine months of 2024 was $5.15 million, a 45.7% decrease from $9.48 million in the same period of 2023.
- The company's cash balance at the end of Q3 2024 was $1.95 million.
Sentiment
Score: 3
Explanation: The document presents a concerning financial picture with significant revenue decline, increased expenses, and a net loss. The strategic shift to accelerate cash settlements, while necessary, introduces uncertainty about long-term profitability. The material weaknesses in internal controls further contribute to a negative sentiment.
Positives
- The company is actively working to accelerate cash settlements of accounts receivable.
- The company has secured a line of credit with a maximum advance amount of $11 million.
- The company is implementing remedial procedures to address material weaknesses in internal control over financial reporting.
Negatives
- The company experienced a significant decrease in revenue and a net loss for both the third quarter and the first nine months of 2024.
- The company's cost of sales and operating expenses increased significantly in Q3 2024.
- The company's gross profit and gross margin decreased substantially in Q3 2024.
- The company has identified material weaknesses in its internal control over financial reporting.
Risks
- The company's ability to continue as a going concern is dependent on additional cash infusions.
- The company's revenue is subject to fluctuations due to weather events and changes in settlement realization rates.
- The company's ability to raise sufficient capital from debt or equity transactions is not guaranteed.
- The company's strategic shift to accelerate cash settlements may result in lower overall revenue.
- The company's material weaknesses in internal control over financial reporting could impact the reliability of its financial statements.
Future Outlook
The company expects the trend of accelerating cash settlements by accepting lower settlement amounts to continue in the short term. The company intends to raise capital for additional acquisitions primarily through equity and debt financings. Management believes that current working capital and current and expected additional financing should be sufficient to fund operations and satisfy obligations for at least one year from the financial statement issuance date.
Management Comments
- Management is in continuous discussions with prospective investors and believes the raising of capital will allow the Company to fund its cash flow shortfalls and pursue new acquisitions.
- Management is committed to the design and successful implementation of internal control over financial reporting as promptly as possible.
Industry Context
The healthcare industry is subject to various factors, including regulatory changes, economic conditions, and competitive pressures. The company's focus on the healthcare sector and its strategy of acquiring undervalued companies is aligned with the trend of consolidation and growth in the industry. The company's reliance on insurance settlements and the impact of weather events on its operations are specific challenges within the healthcare services sector.
Comparison to Industry Standards
- The company's revenue decline and net loss are concerning when compared to industry benchmarks for healthcare service providers, which typically aim for consistent revenue growth and profitability.
- The company's gross margin of 26.19% in Q3 2024 is significantly lower than the industry average for healthcare providers, which often exceeds 50%.
- The company's increased operating expenses, particularly in selling, general, and administrative areas, are higher than industry standards, indicating potential inefficiencies.
- The company's reliance on a line of credit and convertible notes for financing is not uncommon for smaller healthcare companies, but the high interest rates and potential dilution from equity raises are risks that need to be managed.
- The company's strategic shift to accelerate cash settlements by accepting lower amounts is a deviation from typical industry practices, which prioritize maximizing revenue per patient. This strategy may be necessary for short-term cash flow but could impact long-term profitability.
- The company's material weaknesses in internal control over financial reporting are a significant concern and need to be addressed promptly to ensure the reliability of financial statements, which is a key requirement for public companies.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Financial Officer | Previous CFO | Matthew Shafer | 2024-01-02 | New employment agreement |
| Chief Accounting Officer | Former Chief Accounting Officer | Zia Choe | 2024-01-02 | New employment agreement |
Legal Proceedings
- The company is not currently aware of any legal proceedings or claims that it believes will have a material adverse effect on its business, financial condition, or operating results.
Related Party Transactions
- The company has amounts due from previous owners of Edge View, who are current managers of Edge View, totaling $4,979.
- The company had short-term advances from the Chairman of the Board, with a balance of $0 as of September 30, 2024, and $120,997 as of December 31, 2023.
Stakeholder Impact
- Shareholders may be concerned about the company's financial performance and the potential for dilution from equity raises.
- Employees may be affected by the company's cost-cutting measures and strategic shifts.
- Customers may experience changes in service delivery due to the company's operational adjustments.
- Creditors may be concerned about the company's ability to repay its debts.
- Suppliers may be affected by the company's financial challenges and potential changes in purchasing patterns.
Next Steps
- The company will continue to evaluate its estimate of its settlement realization rates in the future.
- The company will continue to implement remedial procedures to address material weaknesses in internal control over financial reporting.
- The company intends to raise capital for additional acquisitions primarily through equity and debt financings.
Key Dates
| Date | Description |
|---|---|
| 2009-03-12 | The company issued a debenture in the principal amount of $20,000. |
| 2014-07-16 | The company acquired Edge View Properties, Inc. |
| 2016-09-12 | The company issued a convertible promissory note in the principal of $80,000. |
| 2017-01-24 | The company issued a convertible promissory note in the principal amount of $80,000. |
| 2018-07-31 | The company acquired Platinum Tax Defenders. |
| 2020-06-02 | The company obtained an SBA loan in the principal amount of $150,000. |
| 2021-05-31 | The company acquired Nova Ortho and Spine, LLC. |
| 2022-09-22 | The company issued a convertible promissory note in the principal amount of $2,600,000. |
| 2023-09-29 | The company and Nova entered into a two-year revolving purchase and security agreement with DML HC Series, LLC. |
| 2023-11-10 | The company sold Platinum Tax. |
| 2024-01-09 | The company effected a 1-for-75,000 reverse split of its outstanding common stock. |
| 2024-04-24 | The company and Nova entered into amendment No. 1 with DML which increased the maximum advance amount to $8,000,000. |
| 2024-05-08 | The company amended its Articles of Incorporation to increase its authorized stock. |
| 2024-05-15 | The company issued 938,908 shares of series Y preferred senior convertible preferred stock. |
| 2024-06-11 | The company entered into a settlement agreement and release of claims with the holder of certain notes and preferred stock and entered into amendment No. 2 with DML which further increased the maximum advance amount to $11,000,000. |
| 2024-09-30 | End of the reporting period for the quarterly report. |
| 2024-11-05 | Date of the report, with 15,036,725 shares of common stock outstanding. |
Keywords
healthcare, orthopedic, revenue, settlement, accounts receivable, financial results, net loss, operating expenses, preferred stock, convertible notes, internal controls, cash flow, debt, acquisitions
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.